COVID-19 - Seraph Research Institute

Welcome to Seraph Research Institute

SARS CoV-2

SARS-CoV-2 is a virulent virus that first appeared in December 2019. Only one month later the World Health Organization declared the outbreak a global health emergency. By early 2021 the virus (most commonly referred to as COVID-19 or coronavirus) had infected 120+ million people globally, resulting in the death of 2.5+ million.

The infection and mortality rates instantly prompted scientists to work voraciously to develop a vaccine. Thankfully there are now several highly efficacious vaccines that have been approved and distributed worldwide. Unfortunately new variants are certain to emerge, which will circumvent the immunity generated by the current vaccines.

According to FDA’s Coronavirus Treatment Acceleration Program (CTAP), apart from the novel therapeutic agents that are in development, scientists are attempting to treat COVID-19 using:

antiviral drugs that treat many viral infections (such as HIV, Herpes, Hepatitis C, and influenza), to keep viruses from multiplying.
immunomodulators designed to mitigate the body’s rampant immune reaction to the virus, in order to prevent it from attacking the patient’s healthy organs.
neutralizing antibody therapies that help individuals fight the virus, which include manufactured antibodies, animal-sourced antibody therapies, and blood-derived products such as convalescent plasma and hyperimmune globulin – which contain antibodies taken from people who have previously had COVID-19.
cell therapy products, including cellular immunotherapies and other types of autologous and allogeneic cells, such as stem cells, and related products.
gene therapy products that seek to modify or manipulate the expression of a gene, or alter the biological properties of living cells for therapeutic use.

0 + Million

COVID-19 INFECTIONS

0 + Million

DEATHS

At this time, different therapeutic approaches are vital in treating COVID-19 because of the limited knowledge about the virus and its ability to mutate quickly. These mutations can lead to variations that are able to escape certain treatments. Therefore it is important to have multiple treatment modalities available, should one form or another not yield the desired results.

In contrast to antibiotics, antiviral drugs have been developed for single diseases. In most cases, these medications target a limited strain-pool of a single virus. In order to develop a single drug for multiple virus strains or variants, or multiple viral infections, a paradigm shift is required in the way we look at antiviral drug development.

Seraph Research Institute is developing a breakthrough antiviral therapy for the treatment and prophylaxis of SARS-CoV-2 infection, utilizing a novel and proprietary mechanism of action. This antiviral therapy was invented by Dr. Serhat, and has successfully demonstrated specific virus killing activity and protection against SARS-CoV-2 in vitro and in vivo studies, conducted in collaboration with Scripps Research – the second largest scientific research institution in the United States.